1. Sweden Stocks

  2. •

    Technology services

  3. •

    Packaged software
RaySearch Laboratories AB Class B

RaySearch Laboratories AB Class B

191.85
SEK
+4.30
(+2.29%)
6.20EPS
35.07P/E
7.33BMarket Cap
Nov 03Next Earn
RaySearch Laboratories AB Class B
IOB:0GRZ
(London Stock Exchange (International))

Recent

price

191.85

P/E

ratio

35.07

div

yld

2.09%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
3.43
3.68
5.36
6.01
8.32
11.6
15.5
17.07
18.3
21.63
19.01
18.72
24.61
29.82
34.77
39.21
37.07
Revenue per Share
0.84
0.5
0.58
-0.61
1.75
2.05
4.42
3.43
2.29
1.47
-0.26
-1.38
0.69
2.38
5.94
6.64
6.22
Basic EPS, GAAP
1.76
-0.85
0.98
-0.74
-0.22
0.22
0.41
-0.04
-1.32
3.15
8.8
5.43
8.96
12.59
13.56
10.47
11.12
Free Cash Flow per Basic Share
0.5
0.5
- -
- -
- -
- -
0.25
- -
- -
- -
- -
- -
- -
- -
2
3
4
Dividend per Share
27.27
27.26
4.8
5.79
7.34
9.32
13.42
16.93
19.18
20.58
20.25
18.33
19.17
21.45
25.57
28.74
23.45
Book Value per Share
8.7
4.93
1.14
0.88
2.55
3.63
6.33
7.52
8.17
8.08
6.05
3.07
4.04
5.97
9.58
12.44
5.86
Tangible Book Value per Share
34
34
34
34
34
34
34
34
34
34
34
34
34
34
34
34
34
Basic Weighted Avg Shares
118
126
182
204
285
398
531
585
627
742
652
642
844
1,022
1,192
1,344
1,270
Sales/Revenue/Turnover
33.87
21.81
13.65
-12.44
24.32
22.84
35.42
30.09
11.1
6.61
3.94
-9.98
3.59
11.98
21.09
24.52
21.78
Operating Margin (%)
- -
34
45
53
54
57
67
70
114
183
214
250
297
286
299
291
- -
Depreciation Expense
29
17
20
-21
60
70
151
118
79
50
-9
-47
24
82
204
228
213
Net Income, GAAP
27.98
40.75
15.71
- -
23.98
24.9
23.56
24.55
13.49
19.48
- -
- -
26.55
25.9
22.59
20.85
21.53
Effective Tax Rate (%)
24.54
13.49
10.91
-10.19
20.98
17.66
28.49
20.1
12.52
6.8
-1.39
-7.37
2.82
7.98
17.07
16.95
16.77
Profit Margin (%)
98
79
89
83
156
172
311
311
267
224
149
- -
-9
127
281
401
180
Working Capital
- -
1
- -
- -
41
38
62
10
7
86
54
491
474
432
395
317
280
LT Debt
197
197
218
197
252
320
460
580
657
705
694
628
657
735
877
985
788
Total Equity
15.05
8.29
8.99
- -
24.01
21.64
34.29
20.08
11.29
6.65
- -
- -
2.7
7.08
15.44
16.73
17.9
Return on Invested Capital (%)
15.14
8.64
9.59
- -
24.68
22.08
34.7
20.11
11.08
6.71
- -
- -
2.68
7.17
16.11
17.15
17.56
Return on Capital (%)
15.14
8.64
9.59
-10.06
26.7
24.59
38.84
22.61
12.69
7.4
-1.3
-7.15
3.7
11.72
25.25
24.47
26.02
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
78
79
79
LT Borrowings
- -
- -
- -
LT Finance Leases
317
299
280
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
7,851
6,490
7,329

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
971
1,009
802
Cash, Cash Equivalents & STI
407
439
213
Accounts Receivable, Net
-9
196
202
Inventories
22
49
40
Total Current Liabilities
570
563
623
Payables & Accruals
- -
- -
- -
ST Debt
78
79
79
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.77%
7.72%
12.39%
Free Cash Flow
312.61%
10.42%
-22.8%
Net Income, GAAP
58.16%
135.06%
11.94%
Sales/Revenue/Turnover
13.76%
16.1%
12.78%
Total Cash Common Dividend
- -
- -
49.85%

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
257
319
293
322
1,192
2025
332
305
332
375
1,344
2026
290
272
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.07
1.79
1.32
1.75
5.94
2025
1.66
0.9
2.09
2
6.64
2026
1.55
0.57
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
2
- -
- -
2
2025
- -
3
- -
- -
3
2026
- -
4.01
- -
- -
- -
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
RaySearch Laboratories AB (publ) (Nasdaq Stockholm: RAY B) develops and markets advanced software solutions for radiation therapy and oncology worldwide. The company offers RayStation, an oncology treatment planning system supporting techniques including intensity-modulated radiation therapy, volumetric modulated arc therapy, proton therapy, brachytherapy and electron beam therapy; RayCare, an oncology information system integrating clinical workflows across radiation therapy, chemotherapy, surgery and imaging; RayIntelligence, a cloud-based analytics platform for data aggregation, analysis and insight generation in cancer centers; RayCommand, a treatment control system linking treatment machines with planning and information systems; RayPlan, a treatment planning system for 3D conformal radiation therapy, IMRT, VMAT, tomotherapy and electron therapy; DrugLog, a verification system for identity and concentration of compounded injectables in cytostatic drug preparation; RayMigrate, a data conversion tool for Pinnacle patient data to RayStation or DICOM formats; µ-RayStation, a platform for small animal irradiation research planning and evaluation; and additional solutions encompassing machine learning applications and liver ablation planning. RaySearch Laboratories maintains subsidiaries in the United States, Singapore, Belgium, France, Germany and the United Kingdom, serving over 2,600 clinics globally with a focus on cancer centers and radiation oncology departments. Founded in 2000 and headquartered in Stockholm, Sweden, the company reports approximately 416 employees and pursues strategic integrations with hardware vendors. In early 2024, RaySearch Laboratories acquired DrugLog from Pharmacolog to expand quality assurance capabilities in chemotherapy; in July 2025, the company entered a strategic partnership with Radiology Oncology Systems to integrate RayStation and RayCare into refurbished linear accelerators, enhancing access in underserved markets; it maintains ongoing collaborations including integration of Vision RT's MapRT surface guided radiation therapy with RayStation, partnerships with IBA, Accuray, Mevion and Varian TrueBeam for market expansion, and joint solutions showcased with GE Healthcare, C-RAD and Leo Cancer Care at ASTRO 2025; in January 2025, Medim placed the first commercial order for DrugLog at The Children's Memorial Health Institute in Warsaw, Poland.

Company News

Company News APIChatGPT

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    RaySearch Laboratories AB (publ) (RSLBF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    RaySearch Laboratories: Interim report April - June 2025

  • prnewswire.com

    Interim report January 1 - March 31, 2025: RaySearch Laboratories

  • prnewswire.com

    RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO

  • prnewswire.com

    Completed placing of shares in RaySearch Laboratories AB (publ)

  • prnewswire.com

    Contemplated placement of existing shares in RaySearch Laboratories AB

  • prnewswire.com

    RaySearch Laboratories: Year-end report 2024

  • prnewswire.com

    RaySearch Laboratories to present ongoing development in liver ablation therapy* at RSNA 2024

  • prnewswire.com

    RaySearch Laboratories: Interim report July - September 2024

  • prnewswire.com

    RaySearch Laboratories: Interim report April - June 2024

  • prnewswire.com

    RaySearch Laboratories: Interim report January 1 - March 31, 2024

  • prnewswire.com

    RaySearch Laboratories: Year-end report 2023

  • prnewswire.com

    RaySearch Laboratories: Interim report January 1 - September 30, 2023

  • prnewswire.com

    Invitation to presentation of RaySearch's interim report for the third quarter of 2023

  • prnewswire.com

    RaySearch Laboratories : Interim report January 1 - June 30, 2023

  • prnewswire.com

    Invitation to presentation of RaySearch's interim report for the second quarter of 2023

  • prnewswire.com

    UMCG in the Netherlands purchases Micro-RayStation for pre-clinical research, RaySearch Laboratories